Blue Trust Inc. Has $77,000 Stake in IQVIA Holdings Inc. $IQV

Blue Trust Inc. raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 64.2% in the 2nd quarter, HoldingsChannel reports. The firm owned 491 shares of the medical research company’s stock after purchasing an additional 192 shares during the quarter. Blue Trust Inc.’s holdings in IQVIA were worth $77,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the business. Canada Pension Plan Investment Board raised its position in shares of IQVIA by 7.3% during the first quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company’s stock worth $810,069,000 after acquiring an additional 312,807 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of IQVIA by 45.7% during the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock valued at $448,686,000 after acquiring an additional 798,534 shares during the period. American Century Companies Inc. lifted its stake in shares of IQVIA by 26.8% during the first quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company’s stock valued at $253,695,000 after acquiring an additional 304,258 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of IQVIA by 2.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company’s stock valued at $251,852,000 after acquiring an additional 40,699 shares during the period. Finally, Pacer Advisors Inc. lifted its stake in shares of IQVIA by 5,036.1% during the first quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company’s stock valued at $153,681,000 after acquiring an additional 854,732 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 0.6%

IQV stock opened at $204.51 on Friday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The business has a 50 day moving average price of $191.41 and a two-hundred day moving average price of $169.23. The company has a market cap of $34.77 billion, a price-to-earnings ratio of 29.60, a P/E/G ratio of 2.26 and a beta of 1.32. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $237.21.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same period in the previous year, the company posted $2.64 EPS. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on IQV shares. Barclays upped their price target on IQVIA from $185.00 to $200.00 and gave the company an “equal weight” rating in a research note on Thursday, October 2nd. Mizuho upped their price target on IQVIA from $190.00 to $225.00 and gave the company an “outperform” rating in a research note on Friday, July 25th. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a research note on Wednesday, October 8th. Redburn Partners set a $214.00 target price on IQVIA in a research note on Wednesday, September 3rd. Finally, HSBC raised IQVIA from a “hold” rating to a “buy” rating and increased their target price for the company from $195.00 to $235.00 in a research note on Thursday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $234.57.

Insiders Place Their Bets

In other news, insider Keriann Cherofsky sold 549 shares of the company’s stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider directly owned 2,910 shares in the company, valued at approximately $557,352.30. This represents a 15.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the business’s stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares of the company’s stock, valued at $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.